Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-15
2011-03-15
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S381000, C514S422000, C514S427000, C548S100000, C548S250000, C548S400000, C548S518000, C548S564000, C548S578000
Reexamination Certificate
active
07906501
ABSTRACT:
Compounds which may be represented by the general formula (I) shown below and in which: R1is a group independently selected from among: CHO, —COOH, —CH2OH R2is hydrogen or a linear or branched C1-C6alkyl group R3is hydrogen or a halogen group selected from among Cl and Br R4is a linear or branched C3-C5alkyl group and the pharmaceutically acceptable salts thereof such as the sodium or potassium salt. The compounds exhibit potent and selective All antagonist activity and are useful for the treatment of any disorders in which elevated synthesis of All or overexpression of the AT1receptor may play a primary pathological role, as in the case of arterial hypertension, congestive cardiac insufficiency, platelet aggregation and disorders associated therewith such as for example myocardial and cerebral infarction, renal ischaemia, venous and arterial thrombosis, peripheral vasculopathy, pulmonary hypertension, diabetes mellitus, diabetic neuropathy, glaucoma and diabetic retinopathy.
REFERENCES:
patent: 0253310 (1988-01-01), None
patent: 0323841 (1989-07-01), None
Carini et al., J. Med. Chem. 1991, vol. 34 (8), pp. 2525-2547.
Prasun K Charravarty, Antihypertensive Agents, Expert Opinion on Therapeutic Patents, Ashley Publications, GB, vol. 5, No. 5, May 1, 1995, pp. 431-458, XP00567227.
Ruth R. Wexler, Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy, Journal of Medicinal Chemistry, vol. 39, No. 3, Feb. 2, 1996.
David J. Dzielak, Comparative pharmacology of the angiotensin II receptor antagonists, Ashley Publications Let., ISSN 1354-3784, 1998.
F. Haber, Berichte Der Deutschen Chemischen Gesellschaft, Verlag Chemie, G.M.B.H., Berlin, 1927.
Kiitiro Utimoto, Palladium-Catalyzed Synthesis of Pyrroles, Tetrahedron Letters, vol. 223, No. 43, pp. 4277-4278, 1981, Pergamon Press Ltd.
Robert A. Benkeser, The Stereochemistry of the Addition of Silicochloroform to Acetylenes, Contribution from the Chemical Laboratories of Purdue University, Mar. 19, 1958, vol. 80, pp. 5298-5300.
Huang-Minlon, A Simple Modification of the Wolff-Kishner Reduction, Contribution from the Chemical Laboratories of Harvard University, Dec. 1946, vol. 68, pp. 2487-2488.
Philip E. Sonnet, Synthesis of Beta-Substituted Pyrroles via 1-(Pyrrol-2-ylmethylene)pyrrolidinium Salts, Entomology Research Division, Agricultural Research Service, U.S. Department of Agriculture, Sep. 2, 1970, J. Org. Chem, vol. 36, No. 7, 1971, pp. 1005-1007.
R.S. L. Chang, In Vitro Pharmacology of L-158, 809, a New Highly Potent and Selective Angiotensin II Receptor Antagonist, The Journal of Pharmacology and Experimental Therapuetics, 1992, vol. 262, No. 1, pp. 133-138.
M. J. Robertson, Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist, Br. J. Pharmacol. (1992), 107, 1173-1180, Macmillan Press Ltd.
Marie-Catherine GRES, Correlation Between Oral Drug Absorption in Humans, and Apparent Drug Permeability in TC-7 Cells, A Human Epithelial Intestinal Cell Line: Comparison with the Parental Caco-2 Cell Line, Parmaceutical Research, vol. 15, No. 5, 1998, pp. 726-733.
Artusi Roberto
Giordani Antonio
Makovec Francesco
Rovati Lucio Claudio
Zanzola Simona
Marschel Ardin
Polansky Gregg
Rottapharm S.p.A.
Roylance Abrams Berdo & Goodman L.L.P.
LandOfFree
Pyrrole derivatives with angiotensin II antagonist activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrole derivatives with angiotensin II antagonist activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole derivatives with angiotensin II antagonist activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2708595